PETMED EXPRESS INC (PETS) Fundamental Analysis & Valuation

NASDAQ:PETS • US7163821066

Current stock price

2.29 USD
-0.07 (-2.97%)
Last:

This PETS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. PETS Profitability Analysis

1.1 Basic Checks

  • In the past year PETS has reported negative net income.
  • In the past year PETS has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: PETS reported negative net income in multiple years.
  • In the past 5 years PETS always reported a positive cash flow from operatings.
PETS Yearly Net Income VS EBIT VS OCF VS FCFPETS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M 40M

1.2 Ratios

  • The Return On Assets of PETS (-73.74%) is worse than 91.06% of its industry peers.
  • PETS's Return On Equity of -197.98% is on the low side compared to the rest of the industry. PETS is outperformed by 74.80% of its industry peers.
Industry RankSector Rank
ROA -73.74%
ROE -197.98%
ROIC N/A
ROA(3y)-2.83%
ROA(5y)3.96%
ROE(3y)-4.97%
ROE(5y)4.31%
ROIC(3y)N/A
ROIC(5y)N/A
PETS Yearly ROA, ROE, ROICPETS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • PETS's Gross Margin of 31.39% is on the low side compared to the rest of the industry. PETS is outperformed by 61.79% of its industry peers.
  • PETS's Gross Margin has been stable in the last couple of years.
  • PETS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y1.28%
PETS Yearly Profit, Operating, Gross MarginsPETS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. PETS Health Analysis

2.1 Basic Checks

  • PETS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, PETS has less shares outstanding
  • The number of shares outstanding for PETS has been increased compared to 5 years ago.
  • PETS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PETS Yearly Shares OutstandingPETS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
PETS Yearly Total Debt VS Total AssetsPETS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of 1.72, we must say that PETS is in the distress zone and has some risk of bankruptcy.
  • PETS has a Altman-Z score (1.72) which is comparable to the rest of the industry.
  • There is no outstanding debt for PETS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.72
ROIC/WACCN/A
WACC8.97%
PETS Yearly LT Debt VS Equity VS FCFPETS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M

2.3 Liquidity

  • PETS has a Current Ratio of 0.89. This is a bad value and indicates that PETS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Current ratio of PETS (0.89) is worse than 78.05% of its industry peers.
  • A Quick Ratio of 0.66 indicates that PETS may have some problems paying its short term obligations.
  • The Quick ratio of PETS (0.66) is better than 60.98% of its industry peers.
Industry RankSector Rank
Current Ratio 0.89
Quick Ratio 0.66
PETS Yearly Current Assets VS Current LiabilitesPETS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. PETS Growth Analysis

3.1 Past

  • PETS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.00%, which is quite impressive.
  • PETS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.05%.
  • PETS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -4.39% yearly.
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1364.43%
Revenue 1Y (TTM)-26.05%
Revenue growth 3Y-6.02%
Revenue growth 5Y-4.39%
Sales Q2Q%-23.26%

3.2 Future

  • The Earnings Per Share is expected to grow by 27.38% on average over the next years. This is a very strong growth
  • PETS is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -3.12% yearly.
EPS Next Y26.23%
EPS Next 2Y42.6%
EPS Next 3Y27.38%
EPS Next 5YN/A
Revenue Next Year-14.05%
Revenue Next 2Y-5.92%
Revenue Next 3Y-3.12%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PETS Yearly Revenue VS EstimatesPETS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
PETS Yearly EPS VS EstimatesPETS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

1

4. PETS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PETS. In the last year negative earnings were reported.
  • The Price/Forward Earnings ratio is 224.51, which means the current valuation is very expensive for PETS.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of PETS is on the same level as its industry peers.
  • The average S&P500 Price/Forward Earnings ratio is at 22.84. PETS is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 224.51
PETS Price Earnings VS Forward Price EarningsPETS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PETS Per share dataPETS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PETS does not grow enough to justify the current Price/Earnings ratio.
  • PETS's earnings are expected to grow with 27.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y42.6%
EPS Next 3Y27.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PETS Dividend Analysis

5.1 Amount

  • PETS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PETS Fundamentals: All Metrics, Ratios and Statistics

PETMED EXPRESS INC

NASDAQ:PETS (4/2/2026, 8:00:01 PM)

2.29

-0.07 (-2.97%)

Chartmill FA Rating
GICS IndustryGroupConsumer Discretionary Distribution & Retail
GICS IndustrySpecialty Retail
Earnings (Last)02-09
Earnings (Next)06-15
Inst Owners35.77%
Inst Owner Change-0.22%
Ins Owners2.8%
Ins Owner Change1.77%
Market Cap49.01M
Revenue(TTM)182.67M
Net Income(TTM)-64.87M
Analysts40
Price Target2.81 (22.71%)
Short Float %5.21%
Short Ratio6.27
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.01
Dividend Growth(5Y)-61.77%
DP-0.04%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-27.33%
Min Revenue beat(2)-28.42%
Max Revenue beat(2)-26.24%
Revenue beat(4)1
Avg Revenue beat(4)18055.8%
Min Revenue beat(4)-28.42%
Max Revenue beat(4)72293.5%
Revenue beat(8)2
Avg Revenue beat(8)9023.49%
Revenue beat(12)2
Avg Revenue beat(12)6013.97%
Revenue beat(16)2
Avg Revenue beat(16)4508.84%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 224.51
P/S 0.27
P/FCF N/A
P/OCF N/A
P/B 1.5
P/tB 2.28
EV/EBITDA N/A
EPS(TTM)-0.3
EYN/A
EPS(NY)0.01
Fwd EY0.45%
FCF(TTM)-1.07
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS8.54
BVpS1.53
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -73.74%
ROE -197.98%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.39%
FCFM N/A
ROA(3y)-2.83%
ROA(5y)3.96%
ROE(3y)-4.97%
ROE(5y)4.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y1.28%
F-Score4
Asset Turnover2.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 69.55%
Cap/Sales 3.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.89
Quick Ratio 0.66
Altman-Z 1.72
F-Score4
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)94.91%
Cap/Depr(5y)89.72%
Cap/Sales(3y)1.98%
Cap/Sales(5y)1.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1364.43%
EPS Next Y26.23%
EPS Next 2Y42.6%
EPS Next 3Y27.38%
EPS Next 5YN/A
Revenue 1Y (TTM)-26.05%
Revenue growth 3Y-6.02%
Revenue growth 5Y-4.39%
Sales Q2Q%-23.26%
Revenue Next Year-14.05%
Revenue Next 2Y-5.92%
Revenue Next 3Y-3.12%
Revenue Next 5YN/A
EBIT growth 1Y-1878.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year55.61%
EBIT Next 3Y48.58%
EBIT Next 5YN/A
FCF growth 1Y-1431.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-340.71%
OCF growth 3Y-36.58%
OCF growth 5Y-34.4%

PETMED EXPRESS INC / PETS Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PETMED EXPRESS INC (PETS) stock?

ChartMill assigns a fundamental rating of 2 / 10 to PETS.


What is the valuation status for PETS stock?

ChartMill assigns a valuation rating of 1 / 10 to PETMED EXPRESS INC (PETS). This can be considered as Overvalued.


How profitable is PETMED EXPRESS INC (PETS) stock?

PETMED EXPRESS INC (PETS) has a profitability rating of 1 / 10.


How financially healthy is PETMED EXPRESS INC?

The financial health rating of PETMED EXPRESS INC (PETS) is 5 / 10.


How sustainable is the dividend of PETMED EXPRESS INC (PETS) stock?

The dividend rating of PETMED EXPRESS INC (PETS) is 0 / 10 and the dividend payout ratio is -0.04%.